You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

CD226 agonist

Showing 1 - 25 of 2,385
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Biliary Cancer, Bile Duct Cancer, Cancer of the Bile Duct Trial run by the National Cancer Institute (NCI) (oxaliplatin,

Not yet recruiting
  • Biliary Cancer
  • +2 more
  • Bethesda, Maryland
    National Institutes of Health Clinical Center
May 13, 2023

Non Small Cell Lung Cancer, Lung Cancer Trial in Bronx (drug, biological, radiation)

Recruiting
  • Non Small Cell Lung Cancer
  • Lung Cancer
  • FLT3 Ligand (CDX-301)
  • +2 more
  • Bronx, New York
    Albert Einstein College of Medicine
Jul 18, 2022

Cancer Trial in Houston (LVGN7409)

Recruiting
  • Cancer
  • LVGN7409
  • Houston, Texas
    MD Anderson Cancer Center
Apr 4, 2022

Metastatic Triple Negative Breast Cancer Trial in Dallas (PLD Chemotherapy, CDX-1140, CDX-301)

Recruiting
  • Metastatic Triple Negative Breast Cancer
  • PLD Chemotherapy
  • +2 more
  • Dallas, Texas
    UT Southwestern Medical Center
Jun 23, 2022

Ovarian Clear Cell Adenocarcinoma, Platinum-Sensitive Ovarian Carcinoma, Recurrent Endometrial Serous Adenocarcinoma Trial in

Not yet recruiting
  • Ovarian Clear Cell Adenocarcinoma
  • +14 more
  • Anti-CD40 Agonist Monoclonal Antibody CDX-1140
  • +4 more
  • Buffalo, New York
  • +1 more
Dec 16, 2022

Metastatic Pancreatic Cancer Trial in Rotterdam (MesoPher, Mitazalimab)

Recruiting
  • Metastatic Pancreatic Cancer
  • MesoPher
  • Mitazalimab
  • Rotterdam, Zuid-Holland, Netherlands
    Erasmus MC
Dec 6, 2022

Advanced/Metastatic Solid Tumors Trial in Kurralta Park, Clayton (ADG206)

Not yet recruiting
  • Advanced/Metastatic Solid Tumors
  • Kurralta Park, South Australia, Australia
  • +1 more
Nov 9, 2022

Recurrent DLBCL, Recurrent DLBCL, Not Otherwise Specified, Recurrent Grade 3b Follicular Lymphoma Trial in Seattle

Recruiting
  • Recurrent Diffuse Large B-Cell Lymphoma
  • +8 more
  • Seattle, Washington
    Fred Hutch/University of Washington Cancer Consortium
Dec 30, 2022

Anatomic Stage IV Breast Cancer AJCC v8, Metastatic Breast Carcinoma, Prognostic Stage IV Breast Cancer AJCC v8 Trial in Los

Recruiting
  • Anatomic Stage IV Breast Cancer AJCC v8
  • +5 more
  • Anti-CD40 Agonist Monoclonal Antibody CDX-1140
  • +3 more
  • Los Angeles, California
    USC/Norris Comprehensive Cancer Center
Jan 31, 2023

Metastatic Pancreatic Adenocarcinoma Trial (odetiglucan, CDX-1140)

Not yet recruiting
  • Metastatic Pancreatic Adenocarcinoma
  • odetiglucan
  • CDX-1140
  • (no location specified)
Jul 29, 2022

Primary Immune Thrombocytopenia (ITP) Trial in Tianjin (TPO-RAs, TPO-RAs combining anti-CD 20 mAb)

Not yet recruiting
  • Primary Immune Thrombocytopenia (ITP)
  • TPO-RAs
  • TPO-RAs combining anti-CD 20 monoclonal antibody
  • Tianjin, China
    Institute of Hematology and Blood Diseases Hospital, Chinese Aca
Feb 7, 2023

Diabetes, Type 2 Trial in Washington (Semaglutide, Placebos)

Recruiting
  • Diabetes Mellitus, Type 2
  • Washington, District of Columbia
    The GW Medical Faculty Associates
Mar 21, 2022

Non-Hodgkin Lymphoma, Relapsed/Refractory Diffuse Large B-cell Lymphoma Trial in United States (NKTR-255 at 1.5 µg/kg, NKTR-255

Recruiting
  • Non-Hodgkin Lymphoma
  • Relapsed/Refractory Diffuse Large B-cell Lymphoma
  • NKTR-255 at 1.5 µg/kg
  • +3 more
  • La Jolla, California
  • +26 more
Jan 10, 2023

Cancer Trial in Beijing, Shanghai (LVGN6051, Pembrolizumab)

Recruiting
  • Cancer
  • Beijing, China
  • +1 more
Nov 24, 2021

Cancer Trial in Beijing (LVGN7409)

Recruiting
  • Cancer
  • LVGN7409
  • Beijing, Beijing, China
    Center Hospital Chinese Academy of Medical Sciences
Dec 7, 2021

Recurrent Acute Myeloid Leukemia, Refractory Acute Myeloid Leukemia Trial in Houston (Anti-OX40 Agonist Monoclonal Antibody

Active, not recruiting
  • Recurrent Acute Myeloid Leukemia
  • Refractory Acute Myeloid Leukemia
  • Anti-OX40 Agonist Monoclonal Antibody PF-04518600
  • +6 more
  • Houston, Texas
    M D Anderson Cancer Center
Jan 25, 2022

Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Carcinoma Trial in United States (SL-172154)

Recruiting
  • Ovarian Cancer
  • +2 more
  • Duarte, California
  • +8 more
Feb 23, 2022

Non-muscle Invasive Bladder Cancer Trial in United States (2141-V11)

Recruiting
  • Non-muscle Invasive Bladder Cancer
  • Basking Ridge, New Jersey
  • +6 more
Dec 7, 2022

Cutaneous Squamous Cell Carcinoma, Squamous Cell Carcinoma of Head and Neck Trial in United States (Drug: SL-172154)

Terminated
  • Cutaneous Squamous Cell Carcinoma
  • Squamous Cell Carcinoma of Head and Neck
  • Drug: SL-172154
  • Los Angeles, California
  • +5 more
May 18, 2022

Metastatic Melanoma Trial in Duarte, Portland, Philadelphia (Bempegaldesleukin (NKTR-214), Nivolumab, 8?Zr-Df-IAB22M2C)

Withdrawn
  • Metastatic Melanoma
  • Bempegaldesleukin (NKTR-214)
  • +2 more
  • Duarte, California
  • +2 more
Jun 28, 2021

Solid Tumors Trial in Worldwide (RO7300490, Atezolizumab)

Recruiting
  • Solid Tumors
  • København Ø, Denmark
  • +10 more
Jan 31, 2023

Metastatic Pancreatic Ductal Adenocarcinoma Trial in Belgium, France, Spain (CD40 agonist mitazalimab in combination with chemo)

Recruiting
  • Metastatic Pancreatic Ductal Adenocarcinoma
  • CD40 agonist mitazalimab in combination with chemotherapy
  • Brussels, Belgium
  • +15 more
Aug 12, 2022

Solid Tumor Trial in Beijing (SHR2150, Anti-Cancer Agent)

Unknown status
  • Solid Tumor
  • Beijing, Beijing, China
    Biotherapeutic Department of Chinese PLA General Hospital
Oct 15, 2020

Locally Advanced Rectal Adenocarcinoma Trial in United States (APX005M, mFOLFOX, and Radiation Therapy 5Gy x 5 days, mFOLFOX and

Recruiting
  • Locally Advanced Rectal Adenocarcinoma
  • APX005M, mFOLFOX, and Radiation Therapy 5Gy x 5 days
  • mFOLFOX and Radiation Therapy 5Gy x 5 days
  • Winston-Salem, North Carolina
  • +2 more
Sep 14, 2021

Response in Patients Treated by Immunotherapy for Advanced

Not yet recruiting
  • Hepatocellular Carcinoma
  • patients with hepatocellular carcinoma
  • (no location specified)
Jan 28, 2022